Currently, there are 98.63M common shares owned by the public and among those 96.91M shares have been available to trade.
The company’s stock has a 5-day price change of 45.37% and -19.33% over the past three months. FATE shares are trading 21.66% year to date (YTD), with the 12-month market performance down to -3.81% lower. It has a 12-month low price of $1.63 and touched a high of $8.83 over the same period. FATE has an average intraday trading volume of 2.35 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 33.07%, 24.23%, and 8.13% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Fate Therapeutics Inc (NASDAQ: FATE) shares accounts for 95.09% of the company’s 98.63M shares outstanding.
It has a market capitalization of $517.93M and a beta (3y monthly) value of 1.92. The earnings-per-share (ttm) stands at -$1.92. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.80% over the week and 8.48% over the month.
Earnings per share for the fiscal year are expected to decrease by -12.94%, and 1.36% over the next financial year.
Looking at the support for the FATE, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on June 17, 2024, with the firm’s price target at $4-$6. Wells Fargo coverage for the Fate Therapeutics Inc (FATE) stock in a research note released on March 27, 2023 offered a Equal Weight rating with a price target of $6. H.C. Wainwright was of a view on January 24, 2023 that the stock is Neutral, while Wedbush gave the stock Neutral rating on January 06, 2023, issuing a price target of $42- $7. Truist on their part issued Hold rating on January 06, 2023.
